Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4249 trials
Conditions Breast Cancer
Phase PHASE3
Enrollment 366
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

This study will compare RC48-ADC to physician choice standard treatment. Participants must have HER2-low breast cancer ,previous use of anthracyclines, and have been treated with one or two systemic chemotherapy regimens following recurrence/metastasis.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: RC48-ADC — RC48-ADC 2.0mg / kg, intravenous drip, once every 2 weeks
  • Drug: Paclitaxel Injection — Administered according to label, as one option for Physician's Choice (determined before randomization)
  • Drug: Docetaxel Injection — Administered according to label, as one option for Physician's Choice (determined before randomization)
  • Drug: Vinorelbine Tartrate Injection — Administered according to label, as one option for Physician's Choice (determined before randomization)
  • Drug: Capecitabine Tablets — Administered according to label, as one option for Physician's Choice (determined before randomization)

Primary Outcomes

  • Progression-free survival (PFS), evaluated by an independent efficacy evaluation committee (within approximately 3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2020-09-29
Completion: 2027-12-31
Eligibility
Age: 18 Years – 70 Years
Sex: ALL
Volunteers: false
Enrollment: 366 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: RemeGen Co., Ltd.
Principal Investigators:
  • Binghe Xu (PRINCIPAL_INVESTIGATOR) - Oncology Hospital, Chinese Academy of Medical Sciences
  • Tao Sun (PRINCIPAL_INVESTIGATOR) - Liaoning Cancer Hospital & Institute
  • Wei Li (PRINCIPAL_INVESTIGATOR) - Jilin University First Hospital
Contact Information
Study Contact:
Binghe Xu, M.D.
010-87788826
bhxu@hotmail.com
Binghe Xu
010-87788826
bhxu@hotmail.com
Oncology Hospital, Chinese Academy of Medical Sciences
Interventions
  • Drug: RC48-ADC — RC48-ADC 2.0mg / kg, intravenous drip, once every 2 weeks
  • Drug: Paclitaxel Injection — Administered according to label, as one option for Physician's Choice (determined before randomization)
  • Drug: Docetaxel Injection — Administered according to label, as one option for Physician's Choice (determined before randomization)
  • Drug: Vinorelbine Tartrate Injection — Administered according to label, as one option for Physician's Choice (determined before randomization)
  • Drug: Capecitabine Tablets — Administered according to label, as one option for Physician's Choice (determined before randomization)
Study Locations (1 sites)
Oncology Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing Municipality 100021 China
Eligibility Criteria
Inclusion Criteria: * Voluntarily agree to participate in the study and sign the informed consent; * Subjects aged 18-70 years (including 18 years and 70 years) and not reaching the 71st birthday were all considered to be ≤70 years old; * Expected survival ≥12 weeks; * Eastern Cooperative Oncology Group(ECOG) physical condition 0 or 1; * For female subjects of child-bearing age women agreed to study during treatment and experimental subjects within 6 months after the end of the treatment period using an approved by the medical contraception (e.g. intrauterine device, the pill or condoms), before the study drug delivery within 7 days of pregnancy blood test must be negative (sterilization surgery or age 60 or more subjects can choose no pregnancy blood test), and must be an lactation. For male subjects: should be sterilized surgically, or agree to use a medically approved contraceptive method during the study period and for 6 months after the end of the treatment period. Control subjects after the end of the treatment period according to the choice of control drugs to determine the length of contraception. * Able to understand the study requirements and be willing and able to follow the study and follow-up procedures. * Bone marrow function: hemoglobin ≥9g/dL; absolute neutrophil count ≥1.5×109/L; white blood cell count ≥3.0×109/L platelet ≥100 ×109/L; * Liver function (according to the normal value of the clinical trial center) : serum total bilirubin ≤1.5 times the upper limit of normal value (ULN); alanine aminotransferase (ALT), aspartate aminotransferase(AST) and Alkaline phosphatase(ALP) were ≤2.5 × ULN in the absence of liver metastasis, and ALT, AST and Alkaline phosphatase(ALP) were ≤5 × ULN in the presence of liver metastasis * Renal function (according to the normal value of the clinical trial center) : serum creatinine ≤1.5×ULN, or calculated by Cockcroft-Gault formula, the creatinine clearance rate (CrCl) ≥60 mL/min; * Cardiac function: American New York college of cardiology (NYHA) grade \< 3; left ventricular ejection fraction ≥50%; * Breast cancer subjects diagnosed by histology and / or cytology are currently at a locally advanced or metastatic stage and cannot be radically removed; * The low expression of HER2 confirmed by the IHC and FISH results of the central laboratory (defined as: IHC 2+ and no amplification of FISH); the subject can provide a specimen of the primary or metastatic tumor site (paraffin wax) for HER2 detection Block, paraffin-embedded section or fresh tissue section can be used); * Previous use of anthracycline drugs; * Received 1 or 2 systemic chemotherapy treatments after relapse / metastasis. Subjects who relapsed during adjuvant chemotherapy or within 12 months after the end of adjuvant chemotherapy were considered to have failed first-line chemotherapy after relapse / metastasis. * Hormone receptors are negative or positive. Hormone receptor-positive subjects need to progress after receiving endocrine therapy after relapse / metastasis or relapse after less than 2 years. Patients who are not suitable for endocrine therapy can be included in this study after undergoing chemotherapy treatment (first-line or second-line); * The imaging evidence confirmed by the investigator that the tumor disease progressed during or after the most recent treatment is required; * There has been no diagnosis of HER2 positive (HER2 IHC 3+ or FISH amplification) * Have not used drugs targeting HER2 (including antibodies, small molecule Tyrosine kinase inhibitor(TKIs) and antibody drug conjugates). * According to the RECIST 1.1 standard, there is at least one measurable lesion. Exclusion Criteria: * Received chemotherapy within 4 weeks before the start of study administration (treatment with nitrosourea and mitomycin C within 6 weeks, oral fluorouracil within 2 weeks), radiotherapy (palliative for bone metastases Local radiotherapy is within 2 weeks before study administration), immunotherapy; received endocrine therapy for breast cancer within 2 weeks before study administration; * The research drug was used within 4 weeks before the start of study administration; * Have undergone major surgery within 4 weeks before the start of study administration; * Have received a live vaccine within 4 weeks before the start of study administration or plan to receive any vaccine during the study period; * Serious cardiovascular and cerebrovascular events occurred within 12 months, including but not limited to unstable angina, myocardial infarction, cerebral hemorrhage, and cerebral infarction (except for asymptomatic and untreated lacunar infarction); * Those who are suffering from heart disease are not suitable for enrollment, including but not limited to arrhythmia and heart failure requiring medical treatment or accompanied by symptoms; * There are other lung diseases requiring treatment or serious, including but not limited to active pulmonary tuberculosis, interstitial lung disease, etc ; * Suffering from active infection requiring systemic treatment; * Have active autoimmune diseases (such as the use of corticosteroids or immunosuppressive drugs, etc.) that require systemic treatment within the past 2 years, allowing related alternative treatments (such as thyroxine, insulin, or the physiology of adrenal or pituitary insufficiency Corticosteroid replacement therapy); * The toxicity of the previous anti-tumor therapy has not been restored to the 0 to 1 level defined by CTCAE version 5.0, of which the neurotoxicity has not been restored to 0; except for hair loss, pigmentation or other researches that do not increase the risk of medication Happening; * Have a clear past or current history of neurological or mental disorders, including epilepsy or dementia; * According to the investigator's judgment, there are concomitant diseases that seriously endanger the safety of the subject or affect the completion of the clinical study; * Positive HIV test results; patients with active hepatitis B or C (HBsAg positive and hepatitis B virus(HBV) DNA titers above the upper limit of normal; Hepatitis C Virus Antibody(HCVAb) positive hepatitis C virus (HCV) RNA titers above the upper limit of normal); * There is a third interstitial fluid that cannot be controlled by drainage or other methods (including a large amount of pleural effusion or ascites); * Known hypersensitivity or delayed allergic reaction to certain components of RC48-ADC or similar drugs; * Subjects who are not suitable for using any of the alternative control drugs; * The presence of brain metastases and / or cancerous meningitis; * Have other malignant tumors within 5 years before signing the informed consent form (except for non-melanoma skin cancer, cervical carcinoma in situ or other tumors that have been effectively treated, except malignant tumors that are considered cured); * Subjects who are estimated to be inadequate for patients to participate in this clinical study or other factors that the investigator believes are inappropriate to participate in this study;
Conditions Breast Cancer, Solid Tumors, Adult
Phase PHASE1, PHASE2
Enrollment 880
Locations 65 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with P13Ka mutations. Part 1 will evaluate STX-478 as monotherapy in participants with advanced solid tumors. Part 2 will evaluate STX-478 therapy as combination therapy with fulvestrant in participants with hormone receptor positive (HR+) breast cancer. Part 3 will evaluate STX-478 as combination therapy with endocrine therapy (aromatase inhibitors, fulvestrant, tamoxifen, or imlunestrant) and a CDK4/6 Inhibitor (either Ribociclib, Palbociclib or Abemaciclib) in participants with HR+ breast cancer. Each study part will include a 28-day screening period, followed by treatment with STX-478 monotherapy or combination therapy.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: STX-478 — STX-478 is a mutant-selective PI3Kα inhibitor
  • Drug: Fulvestrant — Fulvestrant
  • Drug: Ribociclib — Ribociclib
  • Drug: Palbociclib — Palbociclib
  • Drug: Letrozole — Letrozole
  • Drug: Anastrozole — Anastrozole
  • Drug: Exemestane — Exemestane
  • Drug: Tamoxifen — Tamoxifen

Primary Outcomes

  • Number of participants who experience at least 1 Dose Limiting Toxicity (DLT) (First 28 days of treatment)
  • Proportion of participants who experience at least 1 DLT during the first 28 days of treatment (First 28 days of treatment)
  • Objective response rate (ORR) defined as the percentage of participants with partial response or complete response based on RECIST 1.1 (12 months)
  • Incidence of TEAEs/SAEs ≥ grade 2 (12 months)
  • Frequency of TEAEs according to CTCAE v5.0 criteria (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2023-04-17
Completion: 2030-07
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 880 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Eli Lilly and Company
Principal Investigators:
  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) (STUDY_DIRECTOR) - Eli Lilly and Company
Contact Information
Study Contact:
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
1-317-615-4559
LillyTrials@Lilly.com
Physicians interested in becoming principal investigators please contact
clinical_inquiry_hub@lilly.com
Reva Basho
Ellison Clinic at Saint John's
Interventions
  • Drug: STX-478 — STX-478 is a mutant-selective PI3Kα inhibitor
  • Drug: Fulvestrant — Fulvestrant
  • Drug: Ribociclib — Ribociclib
  • Drug: Palbociclib — Palbociclib
  • Drug: Letrozole — Letrozole
Study Locations (65 sites)
Ellison Clinic at Saint John's, Los Angeles, California 90064 United States
UCSF Medical Center at Mission Bay, San Francisco, California 94143 United States
University of Colorado Cancer Center, Aurora, Colorado 80045 United States
Yale-New Haven Hospital, New Haven, Connecticut 06510 United States
Florida Cancer Specialists ORLANDO/DDU, Lake Mary, Florida 32746 United States
Moffitt Cancer Center, Tampa, Florida 33612 United States
Winship Cancer Institute, Emory University, Atlanta, Georgia 30322 United States
University of Iowa, Iowa City, Iowa 52242 United States
Louisiana State University Health Sciences Center, New Orleans, Louisiana 70112 United States
Massachusetts General Hospital, Boston, Massachusetts 02115 United States
Eligibility Criteria
Key Inclusion Criteria: * Has an advanced or refractory solid tumor malignancy that is metastatic or locally advanced and unresectable (as specified by Cohort) * Has a new or recent tumor biopsy (collected at screening, if feasible) or will provide an adequate tissue sample prior to screening * Has a tumor that harbors a documented PI3Kα mutation (cohort specific criterion for cohort-specific mutation types) * Is ≥18 years of age at the time of signing the ICF * Has an ECOG performance status score of 0 or 1 at screening * Has adequate organ function as defined per protocol Key Exclusion Criteria: * Has history (within ≤2 years before screening) of a solid tumor or hematological malignancy that is histologically distinct from the cancers being studied * Has symptomatic brain or spinal metastases * Has an established diagnosis of uncontrolled diabetes mellitus (defined as HbA1c ≥8% and/or FBG ≥140 mg/dL \[7.7 mmol/L\] and/or requiring or required insulin). * Has had prior treatment with PI3K/AKT/mTOR inhibitor(s), except in certain circumstances * Has had treatment with any local or systemic antineoplastic therapy or investigational anticancer agent within 14 days or 4 half-lives, whichever is longer, prior to the initiation of study treatment up to a maximum washout period of 28 days. Endocrine therapy does not require a washout period if the patient is enrolling in a cohort with the same combination endocrine therapy. * Has toxicities from previous anticancer therapies that have not resolved to baseline levels or CTCAE grade ≤1, with the exception of alopecia and peripheral neuropathy. * Has had radiotherapy within 14 days before the initiation of study treatment
Conditions Breast Cancer
Phase PHASE2
Enrollment 72
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

Triple-negative breast cancer (TNBC) is as sociated with shorter overall survival than other breast cancer subtypes, despite the use of curative-intent anthracycline- and taxane-based systemic chemotherapy. Neoadjuvant therapy is now also recognized as the standard treatment for patients with high-risk TNBC. The Keynote-522 study demonstrated that the application of pembrolizumab has raised the pathological Complete Response (pCR) rate in TNBC to over 60%, but nearly 40% of patients still do not achieve pCR. How to further improve the pCR rate in TNBC patients has become a hot topic of current research. Posaconazole is an antibiotic used to prevent invasive Aspergillus and Candida infections and to treat oropharyngeal candidiasis. Our preclinical studies have found that posaconazole can inhibit immune cell-mediated steroidogenesis to restrict TNBC tumor progression. The investigators design and begin a a prospective randomized controlled clinical study to explore the effectiveness of posaconazole in the neoadjuvant treatment of TNBC.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Posaconazole — Day 1 of Cycle 1 only: 300 mg bid; from Day 2, maintenance dose of 300 mg qd, oral administration. 21 days per treatment cycle, for a total of 8 cycles.
  • Drug: Nab-paclitaxel — Nab-paclitaxel 260mg/m2 d1 q21d
  • Drug: Carboplatin — Carboplatin AUC=5-6 d1 q21d
  • Drug: Anthracycline — Epirubicin 90-100mg/m2 d1 q21d or Doxorubicin 50-60mg/m2 d1 q21d
  • Drug: Cyclophosphamide — Cyclophosphamide 1000mg/m2 d1 q21d
  • Drug: PD-1 inhibitors — Toripalimab, Pembrolizumab and Camrelizumab, etc.

Primary Outcomes

  • Pathological Complete Response (24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-05-01
Completion: 2028-02-01
Eligibility
Age: 18 Years – 70 Years
Sex: FEMALE
Volunteers: false
Enrollment: 72 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shandong Cancer Hospital and Institute
Contact Information
Study Contact:
Pengfei Qiu, MD
+86053167626215
qiu.pf@outlook.com
Zhiqiang Shi, MD
+86053167626215
shizhiqiang1024@163.com
Pengfei Qiu
+86053167626215
qiu.pf@outlook.com
Breast Cancer Center Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences
Interventions
  • Drug: Posaconazole — Day 1 of Cycle 1 only: 300 mg bid; from Day 2, maintenance dose of 300 mg qd, oral administration. 21 days per treatment cycle, for a total of 8 cycles.
  • Drug: Nab-paclitaxel — Nab-paclitaxel 260mg/m2 d1 q21d
  • Drug: Carboplatin — Carboplatin AUC=5-6 d1 q21d
  • Drug: Anthracycline — Epirubicin 90-100mg/m2 d1 q21d or Doxorubicin 50-60mg/m2 d1 q21d
  • Drug: Cyclophosphamide — Cyclophosphamide 1000mg/m2 d1 q21d
Study Locations (1 sites)
Breast Cancer Center Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong 250117 China
Eligibility Criteria
Inclusion Criteria: 1. Female, aged ≥ 18 and ≤ 70 years old; 2. first-confirmed TNBC; 3. cT1cN1-3M0 or cT2-4N0-3M0; 4. ECOG score 0-1 points. Exclusion Criteria: 1. Stage I or IV; 2. History of previous breast cancer; 3. Patients with a history of other tumors who have received systemic therapy or local radiotherapy; 4. No immune system disease or connective tissue disease; 5. No history of hormone therapy; 6. Pregnant/lactating.
Conditions TNBC - Triple-Negative Breast Cancer
Phase PHASE3
Enrollment 318
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

Triple-negative breast cancer (TNBC) presents significant challenges due to its limited treatment options and poor efficacy. While neoadjuvant chemotherapy has improved breast-conserving rates and extended survival for TNBC patients, this subtype still faces issues such as restricted treatment modalities, low pathological response rates, and unfavorable prognosis compared to other subtypes. Studies like Keynote522 and IMpassion031 have shown that combining chemotherapy with immunotherapy yields a pCR rate of 64.8% in early-stage high-risk TNBC patients, suggesting that such combinations can offer substantial benefits. However, the low immunogenicity of breast cancer and the lack of clear predictive molecular markers for effective immunotherapy result in suboptimal pCR and objective response rates for this group. Radiotherapy has systemic immune regulatory effects by promoting the release of antigens from tumor cells, enhancing T-cell infiltration, and directly killing tumor cells. Therefore, this study aims to investigate the efficacy and safety of stereotactic radiotherapy combined with PD-1 inhibitors and chemotherapy in the neoadjuvant treatment of TNBC.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Drug: SBRT+PD-1 Inhibitor + Chemotherapy — Radiotherapy: 24Gy/3f, once every other day; Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle; Carboplatin AUC=5, IV, administered on day 1 of each cycle. Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks
  • Drug: PD-1 Inhibitor + Chemotherapy — Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle; Carboplatin AUC=5, IV, administered on day 1 of each cycle. Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks

Primary Outcomes

  • pCR (The time immediately after the complete surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2024-11-01
Completion: 2031-11-01
Eligibility
Age: 18 Years – 65 Years
Sex: FEMALE
Volunteers: false
Enrollment: 318 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: West China Hospital
Collaborators: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Shandong Cancer Hospital and Institute
Contact Information
Study Contact:
Jun Wang, MD
+8618805053037
13882713780@163.com
Jun Wang
+8618805053037
13882713780@163.com
West China Hospital, Sichuan University
Interventions
  • Drug: SBRT+PD-1 Inhibitor + Chemotherapy — Radiotherapy: 24Gy/3f, once every other day; Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle; Carboplatin AUC=5, IV, administered on day 1 of each cycle. Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks
  • Drug: PD-1 Inhibitor + Chemotherapy — Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle; Carboplatin AUC=5, IV, administered on day 1 of each cycle. Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks
Study Locations (1 sites)
West China Hospital, Sichuan University, Sichuan, Chengdu China
Eligibility Criteria
Inclusion Criteria: * 1\. Histologically or cytologically confirmed TNBC (ER-, PR-, HER2-) * 2\. cT1cN1-2M0 or cT2N0-2M0;(AJCC 7th) * 3\. ECOG performance status of 0-1; * 4\. Adequate bone marrow function, defined as: Hb ≥ 9.0 g/dL (90 g/L); ANC ≥ 1,500/mcL (1.5 × 10\^9/L); PLT ≥ 100,000/mcL (100 × 10\^9/L) and no blood transfusion within 3 weeks or growth factor (G-CSF, EPO) therapy within 2 weeks prior to dosing; * 5\. Adequate liver function, defined as: TBIL ≤ 1.5× upper limit of normal (ULN); If no liver metastases, AST and ALT ≤ 2.5× ULN; if liver metastases are present, AST or ALT ≤ 3.0× ULN; ALP ≤ 1.5× ULN; if liver metastases ≤ 2× ULN; Serum albumin ≥ 30g/L; * 6\. Adequate coagulation function: INR or PT, APTT ≤ 1.5× ULN. Participants on anticoagulant therapy should have these laboratory indices closely monitored; * 7\. Adequate renal function, defined as creatinine ≤ 1.5× ULN or Ccr ≥ 50 mL/min calculated using the Cockcroft-Gault formula corrected for body surface area; * 8\. Baseline left ventricular ejection fraction (LVEF) ≥ 50% measured by multiple-gated acquisition (MUGA) or echocardiogram (ECHO); * 9\. No severe organic heart disease or arrhythmias; * 10\. Women of childbearing potential (aged 15-49 years) must have a negative pregnancy test within 7 days before starting treatment. Both male and female participants of reproductive potential must agree to use effective contraceptive measures during the study period and for 3 months after discontinuation of treatment; * 11\. Voluntary signed informed consent by the study participant. Exclusion Criteria: * 1\. Patients with a history of mental illness or those diagnosed with mental disorders at the time of enrollment in the clinical trial. * 2\. Patients with communication barriers due to confusion, aphasia, intellectual disability, or other reasons that prevent them from responding normally. * 3\. Poorly controlled tumor-related pain. * 4\. Patients participating in other clinical studies simultaneously. * 5\. Patients with active or past autoimmune diseases or immunodeficiencies, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, or multiple sclerosis. * 6\. A history of idiopathic pulmonary fibrosis, organizing pneumonia (such as obliterative bronchiolitis), drug-induced pneumonia, or idiopathic pneumonia, or evidence of active pneumonia on chest CT scans at screening. * 7\. Active pulmonary tuberculosis. * 8\. Severe cardiovascular diseases occurring within 3 months prior to the start of study treatment (e.g., NYHA class II or higher heart disease, myocardial infarction, or cerebrovascular accident), unstable arrhythmias, or unstable angina. * 9\. Patients who underwent significant surgical procedures, other than diagnostic surgeries, within 4 weeks prior to the start of the study treatment, or are expected to require significant surgical procedures during the study period. * 10\. Patients who had malignant tumors other than breast cancer within the last 5 years, except for malignancies in the study that have negligible risks of metastasis or death (e.g., a 5-year overall survival rate \> 90%), such as adequately treated cervical carcinoma in situ, non-melanoma skin cancer, ductal carcinoma in situ, or stage I uterine cancer. * 11\. Patients who experienced severe infections within 4 weeks prior to the start of the study treatment, including but not limited to those requiring hospitalization due to infections, bacteremia, severe pneumonia, or any active infection that may impact patient safety. * 12\. Patients who have previously received allogeneic stem cell or solid organ transplants. * 13\. Any other diseases, metabolic dysfunctions, physical examination abnormalities, or clinical laboratory abnormalities that contraindicate the use of the study drug, may affect the interpretation of results, or pose a high risk of treatment complications for the patient.
Conditions Diabetic Nephropathy Type 2
Phase PHASE1, PHASE2
Enrollment 10
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to evaluate the safety and efficacy of a single intra-renal injection of allogeneic umbilical cord-derived mesenchymal stem cells (UC-MSCs) in adults with diabetic nephropathy aged 40 to 65 years. The primary questions the study aims to answer are: 1. Is UC-MSC therapy safe and well-tolerated when administered intra-renally in patients with diabetic nephropathy? 2. Does UC-MSC therapy improve kidney function and modulate inflammatory markers over a 12-month follow-up-period? This is a single-arm, open-label, prospective clinical trial. Participants will receive a one-time intra-renal injection of UC-MSC at a dose of 1 x 10⁶ cells/kg body weight. Participants will attend scheduled follow-up visits at 1, 3, 6, 9, and 12 months post-injections for evaluation of: 1. Renal function (eGFR, serum creatinine, and urine albumin-creatinine ratio) 2. Inflammatory markers (TNF-α, IL-10) 3. Safety outcomes including early and late adverse events The results will be compared to baseline measurements to assess changes after the intervention. If there is a comparison group: Researchers will compare \[arm information\] to see if \[insert effects\]. Participants will \[describe the main tasks participants will be asked to do, interventions they'll be given and use bullets if it is more than 2 items\].

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Biological: Umbilical Cord Mesenchymal Stem Cells — This intervention consists of a single intra-renal injection of allogeneic umbilical cord-derived mesenchymal stem cells (UC-MSCs) administered under imaging guidance. The dose administered is 1 × 10⁶ cells per kilogram of body weight.

Primary Outcomes

  • Incidence of Adverse Events and Serious Adverse Events (From baseline up to 12 months post-injection)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2026-07-01
Completion: 2027-10
Eligibility
Age: 30 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 10 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: PT. Prodia Stem Cell Indonesia
Collaborators: Dr. Sardjito General Hospital, Yogyakarta, Indonesia
Contact Information
Study Contact:
Metalia Puspitasari, MD
+628116110283
puspitasarimetalia@gmail.com
Metalia Puspitasari, MD
+628116110283
puspitasarimetalia@gmail.com
Dr. Sardjito General Hospital
Metalia Puspitasari, MD
Dr. Sardjito General Hospital
Interventions
  • Biological: Umbilical Cord Mesenchymal Stem Cells — This intervention consists of a single intra-renal injection of allogeneic umbilical cord-derived mesenchymal stem cells (UC-MSCs) administered under imaging guidance. The dose administered is 1 × 10⁶ cells per kilogram of body weight.
Study Locations (1 sites)
Dr. Sardjito General Hospital, Yogyakarta, 55284 Indonesia
Eligibility Criteria
Inclusion Criteria: * Diagnosed with Type 2 Diabetes Mellitus (T2DM) * Aged between 40 and 65 years * Diagnosed with chronic kidney disease (CKD) stage III or IV, defined as estimated GFR (eGFR) between 15-60 mL/min/1.73 m² (using CKD-EPI formula) * Renal biopsy showing diabetic nephropathy type IIa-IV * Presence of proteinuria, with urine albumin-to-creatinine ratio (UACR) between 30-3000 mg/g (spot morning urine sample) * Controlled diabetes, defined as HbA1c \<10.0% during screening * Blood pressure within the range of: Systolic 100-160 mmHg, Diastolic 60-100 mmHg * On stable standard therapy for diabetic nephropathy (e.g. ACE inhibitors or ARBs) for at least 12 weeks prior to screening * Willing to provide written informed consent and comply with all study procedures until completion Exclusion Criteria: * Active malignancy or history of cancer * Active liver disease or abnormal liver function (ALT or AST ≥2× upper limit of normal) * Hemoglobin \<8 g/dL or platelet count \<100,000/µL * Serious or unstable cerebrovascular or cardiovascular conditions within the last 6 months * Positive pregnancy test or currently breastfeeding (for women of reproductive age) * Currently receiving immunosuppressive therapy equivalent to ≥20 mg/day prednisone * History of participation in other stem cell research or therapy studies

Small Bowel Diversion

NCT06374368
Recruiting
Conditions Obesity, Type2 Diabetes
Phase NA
Enrollment 80
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

In an effort to replicate metabolic surgery's durable results in metabolic disease while minimizing its risks, two innovative methods has been created. Two surgical methods to create a bowel-to-bowel anastomosis, similar to the type used in current metabolic surgeries. It be to create a jejuno-ileal, side-to-side anastomosis and jejunocolic side-to-side anastomosis. The side-to-side jejuno-ileal anastomosis and side-to-side jejunocolic anastomosis provides two routes for ingested food. The new, shorter route has a malabsorptive effect similar to that seen in Roux en-Y gastric bypass (RYGB) and biliopancreatic diversion (BPD) - procedures which leads to weight loss. Additionally, delivery of non-absorbed macronutrients to the distal ileum, or transverse colon can enhance incretin effect and improve Type 2 Diabetes Mellitus parameters. However, the native route is also preserved, which theoretically reduces the risk of malnutrition, diarrhea, and metabolic derangements seen in other metabolic surgeries.The side-to-side jejuno-ileal anastomosis was already tested in the Pilot Study of the GI Windows Self-Forming Magnetic (SFM) Anastomosis Device for Creation of an Incisionless Small Bowel Bypass for Treatment of Obesity and Diabetes in year 2015 (15). The results of this study demonstrated the safety of this approach without serious adverse events. This non-surgical approach resulted in significant weight loss, favorable changes in insulin and incretin responses to a mixed meal and significant improvement in HbA1c in T2DM (16).In summary, metabolic diseases are a growing pandemic with suboptimal clinical solutions. The surgical side-to-side jejuno-ileal anastomosis and side-to-side jejuno-colic anastomosis without gastrectomy potentially represents a new class of therapy that may produce durable clinical results generally associated with surgery while minimizing its attendant risks.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Procedure: jejuno-ileal diversion — The surgery is performed in general anesthesia with orotracheal intubation. The laparoscopic approach is used. After establishing pneumoperitoneum (insufluation of the abdominal cavity with CO2) the 1th. trocar and laparoscopic camera are introduced through small incision. After visual control of abdominal cavity additional 2-3 trocars for operating instruments are introduced. The site of future anastomosis is identified (45 cm from ligament of Treitz on jejunum and 45 cm for the ileocoecal junction on ileum). The anastomosis between these two parts of jejunum and ileum is created by the means of linear stapler (45 mm).
  • Procedure: jejuno-colic diversion — The surgery is performed in general anesthesia with orotracheal intubation. The laparoscopic approach is used. After establishing pneumoperitoneum (insufluation of the abdominal cavity with CO2) the 1th. trocar and laparoscopic camera are introduced through small incision. After visual control of abdominal cavity additional 2-3 trocars for operating instruments are introduced. The anastomosis is created between jejunum (45 from ligament of Treitz) and transverse colon (behind the liver flexure).

Primary Outcomes

  • Total body weight loss (36 months)
  • Glycated hemoglobin loss (36 months)
  • Diabetes medication loss (36 months)
  • Total cholesterol loss (36 months)
  • Low density lipoprotein loss (36 months)
  • High density lipoprotein loss (36 months)
  • Leptin metabolism evaluation (36 months)
  • Adiponectin metabolism evaluation (36 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2019-05-01
Completion: 2028-12-31
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Ostrava
Collaborators: Institute for Clinical and Experimental Medicine, Vitkovice Hospital
Principal Investigators:
  • Marek Bužga, Doc. (PRINCIPAL_INVESTIGATOR) - University of Ostrava
Contact Information
Study Contact:
Jana Soldánová
+420553462823
jana.soldanova@osu.cz
Marek Bužga
+420553462823
marek.buzga@osu.cz
University of Ostrava
Marek Bužga
University of Ostrava
Interventions
  • Procedure: jejuno-ileal diversion — The surgery is performed in general anesthesia with orotracheal intubation. The laparoscopic approach is used. After establishing pneumoperitoneum (insufluation of the abdominal cavity with CO2) the 1th. trocar and laparoscopic camera are introduced through small incision. After visual control of abdominal cavity additional 2-3 trocars for operating instruments are introduced. The site of future anastomosis is identified (45 cm from ligament of Treitz on jejunum and 45 cm for the ileocoecal junction on ileum). The anastomosis between these two parts of jejunum and ileum is created by the means of linear stapler (45 mm).
  • Procedure: jejuno-colic diversion — The surgery is performed in general anesthesia with orotracheal intubation. The laparoscopic approach is used. After establishing pneumoperitoneum (insufluation of the abdominal cavity with CO2) the 1th. trocar and laparoscopic camera are introduced through small incision. After visual control of abdominal cavity additional 2-3 trocars for operating instruments are introduced. The anastomosis is created between jejunum (45 from ligament of Treitz) and transverse colon (behind the liver flexure).
Study Locations (2 sites)
University of Ostrava, Ostrava, 70300 Czechia
University of Ostrava, Faculty of Medicine, Ostrava, Czechia
Eligibility Criteria
Inclusion Criteria: * age 18-65 years at screening; * Body mass index ≥30 or ≤50kg/m2; * If subject has Type 2 Diabetes: fasting plasma glucose greater than 6,1 mmol/l at time of enrollment if not treated with anti-diabetic medication; * If on no diabetes medications, Hemoglobin A1C between and including 6.5 and 9.0 at time of enrollment. Exclusion Criteria: * Body Mass Index \>50 or \<30 kg/m2; * Diagnosis of Type 2 diabetes less than 6 months; * History of suspected gastrointestinal disease (for example cirrhosis, inflammatory bowel disease); * History of active malignancy (not in remission) with the exception of squamous or basal cell carcinoma of the skin; * Ongoing systemic infection; * Chronic pancreatitis; * Chronic liver disease of any cause; * Poorly controlled psychiatric disease (for example ongoing major depression, schizophrenia, borderline personality, suicidality, psychosis); * Any history of an eating disorder within the past 5 years; * Pre-existing severe comorbid cardio-respiratory disease (for example congestive heart failure, cardiac arrhythmia, coronary artery disease, chronic obstructive lung disease, pulmonary embolism); * uncontrolled hypertension (systolic Blood Preassure \> 150 mm Hg or diastolic Blood Preassure \> 100 mm Hg).
Conditions Diabetes Mellitus, Type 2, Obesity
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to determine the effectiveness of mobile health applications in improving health outcomes and type II diabetes outcomes in type 2 diabetics. This study will involve a 6-month long commitment where participants will be expected to weigh themselves every morning, at the same time, and check their blood glucose readings daily before and after meals for at least three meals in the day.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Factorial Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Other: Mobile health application — Intervention will be with mobile health application

Primary Outcomes

  • Effectiveness of mHealth apps at changing bodyweight assessed by bodyweight measurements over 6 months (6 months)
  • Self-efficacy in weight management assessed by Weight Management and Nutrition Knowledge questionnaire (6 months)
  • Long term change in diabetes via A1c (6 months)
  • Long term change in diabetes via fasting blood glucose (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-10-01
Completion: 2028-07-01
Eligibility
Age: 18 Years – 64 Years
Sex: ALL
Volunteers: true
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: San Diego State University
Contact Information
Study Contact:
Mee Young Hong, PhD
6195942392
mhong2@sdsu.edu
San Diego State University
Robert J Castro, BS
6193636120
rcastro0271@sdsu.edu
San Diego State University
Mee Young Hong, PhD
San Diego State University
Interventions
  • Other: Mobile health application — Intervention will be with mobile health application
Study Locations (1 sites)
San Diego State University, San Diego, California 92182 United States
Eligibility Criteria
Inclusion Criteria: * Diagnosed with type II diabetes for at least 3 months * Between the age of 18-64 * BMI ≥ 25 * Monitors blood glucose regularly (at least once per day) * Owns or has access to a bathroom weight scale * Owns a smartphone and willing to download mobile app Exclusion Criteria: * Does not check blood glucose at least once per day * On medications that promote weight gain such as antipsychotic, antidepressant, and steroid hormone medications. Medications for diabetes such as insulin, thiazolidinediones or sulfonylureas are oka
Conditions Melanoma
Phase PHASE1
Enrollment 120
Locations 46 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to investigate the pharmacokinetics (PK) similarity of Bmab1700 (an intended nivolumab biosimilar), compared with United States (US)-licensed Opdivo, in participants after complete surgical removal of melanoma.

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Bmab1700 — Intravenous infusion.
  • Drug: Opdivo — Intravenous infusion.

Primary Outcomes

  • Area Under the Concentration-Time Curve from Time 0 (Day 1) To Day 29 After the First Dose (AUC0-28days) of Bmab 1700 and Opdivo (Week 0 through Week 4)
  • Area Under the Concentration-Time Curve Over a Dosing Interval (AUC0-tau) of Bmab 1700 and Opdivo (Week 16 through Week 20)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-09-09
Completion: 2028-02-16
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Biocon Biologics UK PLC
Contact Information
Study Contact:
Dr. Gursharan Singh, MBBS; PhD Pharm Med; LLM-IP
+91 80 2808 2066
gursharan.singh@biocon.com
Rajesh CN
+91 9725466994
rajesh.cn@biocon.com
Interventions
  • Drug: Bmab1700 — Intravenous infusion.
  • Drug: Opdivo — Intravenous infusion.
Study Locations (46 sites)
Biocon Investigational Site, Bento Gonçalves, Brazil
Biocon Investigational Site, Ijuí, Brazil
Biocon Investigational Site, Pará, Brazil
Biocon Investigational Site, Porto Alegre, Brazil
Biocon Investigational Site, Rio de Janeiro, Brazil
Biocon Investigational Site 1, Santa Catarina, Brazil
Biocon Investigational Site 2, Santa Catarina, Brazil
Biocon Investigational Site, Santa Catarina, Brazil
Biocon Investigational Site 1, São Paulo, Brazil
Biocon Investigational Site 2, São Paulo, Brazil
Eligibility Criteria
Inclusion Criteria: 1. Participants greater than or equal to (\>=)18 years of age on the day of signing informed consent (follow local regulatory requirements if the legal age of consent for study participation is \>18 years old). 2. Able to understand and willing to provide consent using the study Informed Consent Form (ICF). The voluntarily signed ICF must be obtained before any study-specific procedures are performed. 3. Histologically or cytologically confirmed Stage IIB, Stage IIC, Stage III, or Stage IV melanoma (per American Joint Committee on Cancer, 8th edition) that was completely surgically resected. Complete surgical resection requires removal of all clinically or radiographically evident regional disease. Completion of lymph node dissection is not required unless clinically indicated. Participants must have been surgically rendered free of disease with negative margins on resected specimens documented by appropriate pathology and surgical reports. 4. Complete surgical resection of melanoma must have been performed within 12 weeks before randomization. 5. All participants must have disease-free status documented by a complete physical examination and imaging studies before randomization. 6. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1. 7. Participants must have recovered from melanoma related surgery and its complications before randomization, as per investigator. Exclusion Criteria: 1. History of ocular/uveal melanoma. 2. Participants with an active, known, or suspected autoimmune disease are to be excluded from participation. Participants who have received systemic treatment for an autoimmune disease within the past 2 years before randomization (eg, with disease-modifying agents, corticosteroids, or immunosuppressive drugs) are also excluded. 3. History of active malignancy other than melanoma under study within 3 years before randomization, except for locally curable early-stage cancers (carcinoma in situ or Stage I) that have been curatively treated, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast. 4. Participants with a condition requiring systemic treatment with either corticosteroids \>10 mg daily prednisone or equivalent or other immunosuppressive medications within 14 days before randomization. Inhaled or topical steroids, and adrenal replacement steroid doses \<=10 mg daily prednisone or equivalent, are permitted in the absence of active autoimmune disease 5. Female participants who are pregnant or breastfeeding at the screening visit, or who intend to become pregnant or breastfeed at any time during the study and for 150 days after the last dose of study intervention. 6. Use of an investigational agent or an investigational device within 28 days or 5 half-lives (if half-life is known for the investigational agent), whichever is longer, before randomization or have not recovered from AEs associated with such therapies to Grade 1 or below (based on CTCAE Version 6.0). 7. Any antineoplastic therapy after the complete resection of melanoma under study (eg, chemotherapy, radiation therapy, targeted agents, biotherapy, or limb perfusion). 8. Participants who have received a live/attenuated vaccine within 28 days before randomization. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin, and typhoid vaccine. 9. Expected to receive any other form of antineoplastic therapy during the clinical study. 10. Participants who received previous systemic therapy with any of the following: anti-programmed cell death-protein 1 (PD-1), anti programmed cell death-ligand 1 (PD-L1), anti-programmed cell death-ligand 2 (PD-L2), anti-CD137, anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibodies (including nivolumab or pembrolizumab or ipilimumab or other CTLA-4 targeting agents), chimeric antigen receptor T-cell therapy cells, or any agents targeting the IL-2 pathway or other T-cell co-stimulation/ checkpoint pathways. 11. Treatment with complementary medications (eg, herbal supplements or traditional medicines) with an antineoplastic intent to treat the melanoma within 2 weeks before randomization. Such medications are permitted if they are used as supportive care. 12. Participants will be excluded if clinical assessment or laboratory investigations before randomization demonstrate any of the following: 1. White blood cells: less than (\<) 2000 per microliter 2. Neutrophils: \<1500 per microliter 3. Platelets: \<100 \*103 per microliter 4. Hemoglobin: \<9.0 gram per deciliter (g/dL) 5. Participants with estimated creatinine clearance (CrCl) (measured or calculated) less than or equal to (\<=) 40 milliliter per minute (mL/min). • CrCl: using the Cockroft-Gault formula: * Female CrCl = \[(140 - age in years) \* weight in kilogram (kg) \* 0.85\] divided by (72 \* serum creatinine in milligram per deciliter \[mg/dL\]) * Male CrCl = \[(140 - age in years) \* weight in kg \* 1.00\] divide by (72 \* serum creatinine in mg/dL) 6. Aspartate aminotransferase: greater than (\>) 2.5 \* upper limit of normal (ULN) 7. Alanine aminotransferase: \>2.5 \* ULN 8. Total bilirubin \>1.5 \* ULN (except participants with Gilbert Syndrome who must have a total bilirubin level of \<3.0 \* ULN) 13. Participants positive for human immune deficiency virus (HIV-1 and HIV-2) tests. Screening for HIV infection must adhere to local regulatory guidelines and confirm the absence of HIV-1 and HIV-2 infection. Note: Participants with documented HIV infection may be enrolled where required by local regulatory or ethics committee guidance, provided all the following criteria are met: * The participant is on stable antiretroviral therapy for at least 12 weeks prior to the first dose of study treatment, and no planned change in antiretroviral therapy regimen during the PK sampling period. * Adequate immune function, defined as: CD4+ T cell count greater than or equal to (\>=) 350 cells per millimeter cube (cells/mm\^3) at screening * No history of uncontrolled or recent Acquired Immunodeficiency Syndrome (AIDS) defining illness, that is \[ie\], no active AIDS defining condition within the past 12 months * Undetectable viral RNA load 14. Participants having positive test result for hepatitis B virus (HBV) or hepatitis C virus (HCV) indicating presence of virus, eg, hepatitis B surface antigen (Australia antigen) positive, or hepatitis C antibody (anti- HCV) positive (except if HCV RNA negative). 15. Participants with history or current evidence of any clinically significant medical condition (including but not limited to physical examination, vital signs, electrocardiogram \[ECG\] findings, laboratory results), or ongoing therapy, that could confound study results, increase participation risk, or are deemed not in the participant's best interest by the treating investigator. 16. Known history of allergy or hypersensitivity to IMP components. 17. Known history of severe hypersensitivity reaction (Grade \>=3) to any monoclonal antibody. 18. Participants who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness. 19. Has documented or known current alcohol/drug abuse that precludes the participant's ability to adhere to the protocol. 20. Prisoners or participants who are involuntarily incarcerated.
Conditions Type 2 Diabetes
Phase NA
Enrollment 160
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

The overall aim of the present study is to investigate the effectiveness of implementing a 1-year time-restricted eating (TRE)-based intervention on glycaemic control, body weight and composition, cardiometabolic risk factors, and behaviour in individuals with overweight/obesity and type 2 diabetes (T2D).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: Time restricted eating — 3 months (12 weeks) strict TRE intervention: Participants will be instructed to reduce their eating window by minimum 3 hours compared to habitual eating, with an eating window below 10 hours. The timing of the eating window is self-selected but should be placed between 6 am and 8 pm. Diet during the eating window is ad libitum with no further dietary restrictions. 9 months (40 weeks) individually adjusted TRE intervention: An individual plan will be made based on participants' experiences during the strict TRE. Different choices of individual adjustment and support will be provided, including 1) eating window adjustments and the possibility of 'days off', 2) provision of a list of allowed calorie and caffeine free beverages that can be consumed outside the window, 3) continued opportunity to participate in peer-support group meetings, 4) extra phone calls with a project worker to discuss challenges or strategies to continue with TRE etc., and 5) further involvement of relatives.

Primary Outcomes

  • Change in HbA1c (mmol/mol) (Change from baseline to 3-months of intervention (strict TRE))
  • Change in HbA1c (mmol/mol) (Change from baseline to the end of the intervention (12 months))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-03-21
Completion: 2026-05-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 160 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Steno Diabetes Center Copenhagen
Collaborators: University of Leeds, Salk Institute for Biological Studies, University of Copenhagen, Glostrup University Hospital, Copenhagen
Principal Investigators:
  • Jonas S Quist, PhD (PRINCIPAL_INVESTIGATOR) - Steno Diabetes Center Copenhagen
Contact Information
Study Contact:
Jonas S Quist, PhD
+45 26176064
jonas.salling.quist@regionh.dk
Jonas S Quist, PhD
+4526176064
jonas.salling.quist@regionh.dk
Steno Diabetes Center Copenhagen
Interventions
  • Other: Time restricted eating — 3 months (12 weeks) strict TRE intervention: Participants will be instructed to reduce their eating window by minimum 3 hours compared to habitual eating, with an eating window below 10 hours. The timing of the eating window is self-selected but should be placed between 6 am and 8 pm. Diet during the eating window is ad libitum with no further dietary restrictions. 9 months (40 weeks) individually adjusted TRE intervention: An individual plan will be made based on participants' experiences during the strict TRE. Different choices of individual adjustment and support will be provided, including 1) eating window adjustments and the possibility of 'days off', 2) provision of a list of allowed calorie and caffeine free beverages that can be consumed outside the window, 3) continued opportunity to participate in peer-support group meetings, 4) extra phone calls with a project worker to discuss challenges or strategies to continue with TRE etc., and 5) further involvement of relatives.
Study Locations (1 sites)
Steno Diabetes Center Copenhagen, Herlev, Denmark 2730 Denmark
Eligibility Criteria
Inclusion Criteria: * Age: ≥18 years * Overweight or obesity (BMI ≥25 kg/m2) * T2D with HbA1c\>53 mmol/mol * Habitual eating window ≥12 h/day (incl. foods/snacks and energy-containing beverages) Exclusion Criteria: * Bariatric surgery or planned bariatric surgery within study duration * Use of fast acting insulin and combination insulin products * Habitual CGM use * A wish to adhere to Ramadan * For women: current/planned pregnancy or lactation * Alcohol or drug abuse (judged by investigator) or treatment with disulfiram * Severe hypoglycaemia within last year (Severe hypoglycaemia, as defined by the American Diabetes Association (ADA), denotes severe cognitive impairment requiring external assistance for recovery) * Inability to understand written and oral information in Danish * Unable or unwilling to adhere to TRE; for instance, due to competing medical conditions. * Medical condition which, based on investigators assessment, challenges participation including but not limited to severe heart, vascular or lung disease, cancer, chemotherapy, psychiatric, gastrointestinal, rheumatic, or endocrine diseases etc. * Concomitant participation in other intervention study * Inability to perform neuropsychological tests (e.g., severe vision and hearing impairment that can-not be improved with aids such as glasses and hearing aids, or language barrier.) Exclusion criteria for the sub-study: * Magnetic resonance imaging (MRI) contraindications based on the MR department's exclusion criteria including pacemaker or other implanted electronic devices, implanted metal objects not compatible to MRI scanning and severe claustrophobia * Participants who do not wish to be informed about accidental findings by MR.
Conditions Cardiovascular Diseases, Type 2 Diabetes...
Phase NA
Enrollment 90
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

This study is a three-arm, parallel-group, randomised controlled trial evaluating the effect of using cardiac CT imaging or polygenic risk score in cardiovascular risk factor modification in patients with diabetes.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Other: CTCA results — Participants who are assigned to CTCA group will receive their CTCA results
  • Other: PRS results — Participants who are assigned to PRS group will receive their PRS results

Primary Outcomes

  • Change in non-calcified plaque volume, with Bonferroni correction at 12 months (From baseline CT to the end of study at 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-07-25
Completion: 2026-08
Eligibility
Age: 40 Years and older
Sex: ALL
Volunteers: false
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Monash University
Principal Investigators:
  • Stephen J Nicholls, MBBS, PhD (PRINCIPAL_INVESTIGATOR) - Monash University
Contact Information
Study Contact:
Domenic Sacca
0423245187
domenic.sacca@monash.edu
Mary-Anne Austin
+61 3 7511 1243
Maryanne.Austin@monashhealth.org
Victorian Heart Hospital
Stephen J Nicholls
Victorian Heart Hospital
Interventions
  • Other: CTCA results — Participants who are assigned to CTCA group will receive their CTCA results
  • Other: PRS results — Participants who are assigned to PRS group will receive their PRS results
Study Locations (1 sites)
Victorian Heart Hospital, Melbourne, Victoria 3168 Australia
Eligibility Criteria
Inclusion Criteria: * Age 40 years or older * Established diagnosis of T2DM * Having acceptable imaging quality as deemed by the VHI-AICL * Able to have a PRS calculated Exclusion Criteria: * Unable to provide written informed consent. * Unwilling to be followed for serial evaluation * Clinically manifest CV disease * Evidence of clinically significant coronary disease on CT that would preclude masking from participant's treating clinician for the duration of the study on the grounds of safety, including but not limited to, equal/greater than 50% in the left main coronary artery or equal/greater than 70% in any epicardial coronary artery * Unable to participate in the study or complete protocol required assessments in the opinion of the Investigator
Conditions Diabetes Mellitus, Type 2 DM
Phase PHASE4
Enrollment 800
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

The efficacy and safety of a triple-pill combination therapy for advanced type 2 diabetes care. The study aims to assess the impact of 3 Oral Anti Diabetic (OAD) drugs on metabolic control, patient compliance, weight management, quality of life, diabetic treatment satisfaction and frequency of hypoglycemic events by combining them into a fixed-dose single pill.

Design

Study type: Interventional Phases: Phase4 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Combination Product: Empagliflozin+Linagliptin+Metformin — Scarcity of local population data on triple drug combination's impact on compliance, efficacy and safety in diabetic patients

Primary Outcomes

  • Changes in HbA1c levels (03 months, 06 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2025-10-30
Completion: 2026-06-30
Eligibility
Age: 18 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 800 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Nabiqasim Industries (Pvt) Ltd
Contact Information
Study Contact:
Ahmad Shahzad
0329
NQmedicalaffairs@gmail.com
Faisalabad clinics
Ahmad Shahzad
Faisalabad clinics
Aamir Shoukat
Faisalabad clinics
Interventions
  • Combination Product: Empagliflozin+Linagliptin+Metformin — Scarcity of local population data on triple drug combination's impact on compliance, efficacy and safety in diabetic patients
Study Locations (2 sites)
Faisalabad clinics, Faisalabad, Punjab Province Pakistan
Aap ka Clinic, Lahore, Punjab Province Pakistan
Eligibility Criteria
Inclusion criteria 1. Patients of any gender 2. Patients aged between 18-80 years 3. Patients having HbA1c 8 % or above 4. Patients diagnosed with type II diabetes (more than at least 06 months) 5. Patients already on at least 02 or more anti-diabetic agents 6. Patients not allergic to empagliflozin, linagliptin, or metformin Exclusion criteria 1. Patients with age less than 18 2. Patients with Type-I diabetes 3. Patients having diabetes for less than 06 months 4. Patients on GLP-1 and GIP 5. Patients who are pregnant or lactating females 6. Patients with decompensated chronic liver disease (DCLD) 7. Patients with eGFR less than 30 ml 8. Patients with end-stage heart failure (NYHA Class 4) 9. Patients who are allergic to empagliflozin, linagliptin, or metformin 10. Patients who are not willing to consent 11. Patients who are unable to give medical history
Conditions Spinal Cord Injury, Cardio Vascular Dise...
Phase PHASE1
Enrollment 6
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

Cardiometabolic Disease (CMD) is the silent killer within the spinal cord injury/disease (SCI/D) population. Many SCI/D patients' initial CMD presentation is with a heart attack, stroke, or sudden cardiac death, highlighting the need for interventions to reduce CMD risk. CMD contributes to 46% of deaths, with 30-50% of the SCI/D population living with undiagnosed CMD. Treating CMD risk is more challenging in the SCI/D population due to prolonged inactivity, inability to exercise, and excessive caloric intake to expenditure ratio. Identifying accessible and inclusive strategies to combat CMD risk in the SCI/D population is a compelling and urgent health priority. Blood flow restriction (BFR) exercise involves applying inflatable cuffs to the proximal end of an individual's limbs. Changes to the amount of blood flowing into and out of the limb lead to a low oxygen environment within the limb, shifting the way the muscles can produce the energy required to function, increasing the benefits of low- and moderate-intensity exercise. Coupling BFR with Functional electrical stimulation cycling (FES-cycling), a commonly used rehabilitation tool within the SCI population, could improve FES-cycling's short- and long-term benefits without reducing the accessibility and inclusiveness of long-term exercise prescription. Although preliminary BFR research in the SCI/D has identified positive muscular improvements, whether FES-cycling coupled with BFR can be safely prescribed or feasibly implemented long-term within the SCI/D population is unknown. The proposed project aims to determine the safety and feasibility of FES-cycling coupled with BFR for 20 minutes of moderate-intensity exercise among adults with chronic spinal cord injury/disease (SCI/D). The research team aims to implement pre-test, eight exercise sessions, and post-test across 6-weeks. Criteria for success include no adverse or severe adverse events not alleviated by ceasing exercise (safety), a 1 to 8 ratio of participants screened to participants eligible (recruitment success), and participants successfully completing all exercise sessions (participant retention).

Design

Study type: Interventional Phases: Phase1 Allocation: Non Randomized Intervention model: Crossover Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Device: Blood Flow Restriction — Blood Flow Restriction (BFR) exercise is a training method where a specialized cuff or band is applied to the top of a limb (arm or leg) to partially restrict blood flow during exercise.
  • Other: Functional Electrical Stimulated Cycling — Electrical impulses will be sent to the muscles of the lower leg during cycling to facilitate muscular contractions.

Primary Outcomes

  • Participant Retention (Six weeks - From enrollment to the end of the exercise protocol.)
  • Safety - Skin Checks (6 weeks)
  • Safety - Adverse Event Report (6 weeks)
  • Recruitment Rate (2 to 3 months, depending on how successful the recruitment process is.)
  • Change in CMD Risk Profile - Lipid Profile (Six weeks - From enrollment to the end of the exercise protocol.)
  • Participant Perspectives and Experience (6 weeks)
  • Safety - Heart Rate (Six weeks - From enrollment to the end of the exercise protocol.)
  • Safety - Blood Pressure (Six weeks - From enrollment to the end of the exercise protocol.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-06-15
Completion: 2027-09-30
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 6 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Dr. B. Catharine. Craven
Collaborators: CAN-TAP-TALENT (CIHR Stream)
Contact Information
Study Contact:
Thomas P Walden, Ph.D
4165973422
thomas.walden@uhn.ca
Katherine Chan, MSc
4165973422
Katherine.chan@uhn.ca
Thomas P Walden, Ph.D
4165973422
thomas.walden@uhn.ca
Lyndhurst Centre
Interventions
  • Device: Blood Flow Restriction — Blood Flow Restriction (BFR) exercise is a training method where a specialized cuff or band is applied to the top of a limb (arm or leg) to partially restrict blood flow during exercise.
  • Other: Functional Electrical Stimulated Cycling — Electrical impulses will be sent to the muscles of the lower leg during cycling to facilitate muscular contractions.
Study Locations (1 sites)
Lyndhurst Centre, Toronto, Ontario M4G 3V9 Canada
Eligibility Criteria
Inclusion Criteria: * Adult (≥ 18 to ≤ 75yrs) * Male or female * Chronic Injury (\>1yr) * Diagnosis of SCI at levels between C5 to T10 (AIS A-D) with traumatic or non-traumatic etiology. * ≥3 Cardiometabolic risk parameters Exclusion Criteria: * A prior or current history of venous thromboembolism * Pressure injury of the pelvis, mid to upper thigh region, or foot * Managing a lower limb fracture * Any history of embolic stroke * Myocardial infarction * Current untreated hypertension * Language, psychiatric, cognitive, or communicative disability (e.g., traumatic brain injury) that compromises the participant's autonomy to voluntarily join the study, follow its instructions and/or operate the device. * Current alcohol or street drug use disorder. * Current use of an anticoagulant medication. * Frequent episodes of autonomic dysreflexia unresponsive to therapy (e.g., 3-5 times a week). * Unresolved deep vein thromboembolism (VTE) in the past six months. * Severe spasticity preventing the necessary range of motion for cycling. * Active implantable medical device (e.g., pacemaker, ITB pump). * Inability to provide informed consent. * Severe active concurrent medical conditions (e.g., skin or respiratory infections, lung, pressure sores). * Unstable spine or unhealed limbs or pelvic fractures. * Active heterotopic ossification interfering with the lower extremity range of motion.